Treatment of Relapsed or Refractory Neuroblastoma With Ex-Vivo Expanded and Activated Haploidentical NK Cells and Hu14.18-IL2
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 25 Oct 2017
At a glance
- Drugs Monoclonal antibody ch14 18 interleukin-2 fusion protein (Primary) ; Natural killer cell therapy
- Indications Neuroblastoma
- Focus Adverse reactions
- 18 Oct 2017 Planned initiation date changed from 1 Oct 2017 to 1 Nov 2017.
- 06 Sep 2017 Planned initiation date changed from 1 Sep 2017 to 1 Oct 2017.
- 14 Jul 2017 New trial record